<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40972554</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2058-1742</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>European heart journal. Quality of care &amp; clinical outcomes</Title><ISOAbbreviation>Eur Heart J Qual Care Clin Outcomes</ISOAbbreviation></Journal><ArticleTitle>Impact of baseline risk of death or hospitalisation on effectiveness of revascularisation in patients with ischaemic left ventricular dysfunction - a prespecified analysis of REVIVED-BCIS2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">qcaf108</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjqcco/qcaf108</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Randomized trials have failed to show a consistent benefit of revascularization in patients with ischaemic cardiomyopathy. This study aimed to investigate whether a participant's baseline risk introduces heterogeneity in the treatment effect of percutaneous coronary intervention (PCI).</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">The REVIVED-BCIS2 trial randomised 700 participants with ischaemic cardiomyopathy to PCI plus optimal medical therapy (OMT) versus OMT alone, 263 (37.6%) of whom experienced the primary outcome (all-cause mortality or hospitalisation due to heart failure) during a median follow-up of 41 months. Pre-randomisation data were used to develop a prediction model for the primary outcome and evidence for heterogeneity of the trial intervention effect was investigated. The prediction model included 12 predictors and showed acceptable discrimination (C statistic: 0.69, 95% CI 0.66 to 0.72) and calibration (calibration slope: 0.79, 95% CI 0.64 to 0.95). Overall, there was no statistical evidence that the baseline risk score modified the trial intervention effect (pinteraction=0.21) on the primary outcome. For the secondary outcome of cardiovascular death or hospitalisation due to heart failure, weak evidence emerged that the baseline risk modified the trial intervention effect (pinteraction=0.044). Participants with lower baseline risk trended towards a greater benefit from PCI compared to participants with higher risk scores.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Baseline risk did not influence the effect of revascularisation in preventing all-cause mortality or hospitalisation due to heart failure. A trend was observed that lower baseline risk might be associated with more benefit of revascularisation in preventing cardiovascular death or hospitalisation due to heart failure.</AbstractText><AbstractText Label="CLINICALTRIALS.GOV IDENTIFIER" NlmCategory="UNASSIGNED">NCT01920048.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ovesen</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4870-4475</Identifier><AffiliationInfo><Affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6207-6604</Identifier><AffiliationInfo><Affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine &amp; Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guy's and St. Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1266-3288</Identifier><AffiliationInfo><Affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharples</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perera</LastName><ForeName>Divaka</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6362-1291</Identifier><AffiliationInfo><Affiliation>British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine &amp; Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guy's and St. Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01920048</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Qual Care Clin Outcomes</MedlineTA><NlmUniqueID>101677796</NlmUniqueID><ISSNLinking>2058-1742</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40972554</ArticleId><ArticleId IdType="doi">10.1093/ehjqcco/qcaf108</ArticleId><ArticleId IdType="pii">8256345</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>